Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (DE:8QQ)
FRANKFURT:8QQ
AbCellera Biologics (8QQ) Stock Price & Analysis
0 Followers
8QQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.60 - €7.20
Previous Close€3.81
Volume0.00
Average Volume (3M)569.00
Market Cap
€1.15B
Enterprise Value€514.66M
Total Cash (Recent Filing)$760.59M
Total Debt (Recent Filing)$84.49M
Price to Earnings (P/E)N/A
Beta0.82
Next Earnings
May 07, 2024EPS Estimate
-€0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding289,355,867
10 Day Avg. Volume54
30 Day Avg. Volume569
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.23
Price to Sales (P/S)93.45
Price to Cash Flow (P/CF)-15.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue27.11
Enterprise Value/Gross Profit11.49
Enterprise Value/Ebitda-7.21
Forecast
1Y Price Target
€12.80Price Target Upside236.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
AbCellera Biologics News
PremiumCompany Announcements
Peter Thiel Retires from AbCellera Board, Dr. Andrew Lo Steps In
PremiumCompany Announcements
AbCellera Biologics Reviews 2023 Financial PerformanceBulls Say, Bears Say
Bulls Say
Financial HealthAbCellera's strong financial position, with over $1 billion in liquidity, positions the company to effectively invest in its innovative programs and strengthen its operational capabilities.
Pipeline DevelopmentAbCellera's internal pipeline, especially with T-cell engagers, is anticipated to attract major Pharma interest, potentially leading to lucrative licensing deals and bolstering the stock.
Strategic PartnershipsAnalyst expects a strategic partnership deal to materialize, leveraging AbCellera's extensive TCE assets and their potential in cancer treatment, which could significantly enhance shareholder value.
Bears Say
Company RestructuringABCL disclosed a 10% workforce reduction to focus resources on clinical development of its internal and partner programs.
Operational EfficiencyThe company's downsizing move, while optimizing resources for clinical development, indicates potential challenges in sustaining its previous operational scope.
Research And DevelopmentManagement continues to see value in AI drug development, but key breakthroughs likely remain further away.
---
Options Prices
Currently, No data available
---
Ownership Overview
47.64% Insiders
4.50% Mutual Funds
1.32% Other Institutional Investors
46.54% Public Companies and
Individual Investors
8QQ FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was €3.60 and its highest was €7.20 in the past 12 months.
What is AbCellera Biologics’s market cap?
Currently, no data Available
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Feb 20, 2024. The company reported -€0.151 earnings per share for the quarter, missing the consensus estimate of -€0.108 by -€0.042.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -€0.12.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 292,782,170 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -€0.151 in its last earnings report, missing expectations of -€0.108. Following the earnings report the stock price went down -11.243%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Among the largest hedge funds holding AbCellera Biologics’s share is Baker Bros Advisors LP. It holds AbCellera Biologics’s shares valued at 131M.
---
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.80 (236.30% Upside)
€12.80 (236.30% Upside)
Blogger Sentiment
Bullish
DE:8QQ Sentiment 66%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $151.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.12%
12-Months-Change
Fundamentals
Return on Equity
-12.27%
Trailing 12-Months
Asset Growth
-3.43%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
---
8QQ Company Deck
---
8QQ Earnings Call
Q4 2024
0:00 / 0:00
---
8QQ Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
8QQ Stock 12 Months Forecast
Average Price Target
€12.80
▲(236.30% Upside)
Technical Analysis
AbCellera Biologics
―
Adaptive Biotechnologies
―
Vertex Pharmaceuticals
―
Arcturus Therapeutics
―
Amgen
―
Best Analysts Covering 8QQ
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-39.20%
reiterated a buy rating 2 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -39.20% per trade.
---